The analysis was based on aggregated trial-level data rather than individual patient data, and variations in study populations, trial design, and baseline cardiovascular risk may have influenced the observed outcomes
Sntomas como dolor abdominal intenso (posible pancreatitis), dolor en cuadrante superior derecho/fiebre/ictericia (enfermedad biliar), vmitos persistentes (riesgo de deshidratacin y lesin renal), o cambios repentinos en la visin (retinopata) requieren evaluacin mdica inmediata
#ADA2026 #PASID #Obesity #Diabetes #GLP1 #Survodutide #CagriSema #Orforglipron #AZD5004 #MASLD #MASH To view or add a comment, sign in PASID American Diabetes Association 2026 | Breaking News Beyond GLP-1: The New Race in Obesity, Diabetes & Metabolic Liver Disease ADA 2026 is making one thing very clear: The future of metabolic medicine is no longer about GLP-1 alone
Particularly when used alongside UV exposure
It plays a key role in cellular metabolism and is especially popular for supporting fat loss, improving endurance, and enhancing recovery
BIBLIOGRAFIA Yarizadh, H., Shab-Bidar, S., Zamani, B., Vanani, A
